South and Central America Cancer Therapeutics Market Report (2021–2031) by Scope, Segmentation, Dynamics, and Competitive Analysis
Description
The cancer therapeutics market size is expected to reach US$ 24,601.57 million by 2031 from US$ 11,494.24 million in 2024. The market is estimated to record a CAGR of 11.59% from 2025 to 2031.
Executive Summary and South and Central America Cancer Therapeutics Market Analysis:
The cancer therapeutics market in South and Central America is witnessing steady growth with increasing prevalence of cancer, the expansion of healthcare infrastructure, and augmented government programs for cancer treatment. Progress in targeted therapies, immunotherapies, and personalized medicine are improving the outcomes of the treatments in the region. Market growth is driven by Brazil and Argentina due to higher healthcare spending and accessibility of advanced treatments. Companies are focusing on strategic initiatives such as partnerships, clinical trials, and product launches to increase their regional footprint. With the market continuing to attract investment and create awareness, the market is likely to witness moderate but consistent growth over the next few years, with rich opportunities for innovation and market penetration.
South and Central America Cancer Therapeutics Market Segmentation Analysis:
Key segments that contributed to the derivation of the cancer therapeutics market analysis are therapy type, indication, and distribution channel.
By therapy type, the cancer therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment dominated the market in 2024. In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the market in 2024.
South and Central America Cancer Therapeutics Market Outlook
The South and Central America cancer therapeutics market is growing, with Brazil and Argentina becoming the contributors of market growth. In May 2022, In Brazil, pharmaceutical group Eurofarma has signed an agreement with Shanghai Henlius Biotech to manufacture biosimilars, thus making more cancer therapies available in South and Central America. The Brazilian government has also funded a CAR T-cell treatment trial for blood cancers undertaken by the University of São Paulo and the Butantan Institute. In Argentina, Hugo Sigman's Grupo Insud is a major biotechnology company, with its mAbxience subsidiary developing biosimilars for oncology. The Argentine government has been spearheading cancer research through initiatives like the National Cancer Institute with an aim to improve the delivery of treatment and promote public-private partnerships. The efforts indicate the dynamic and evolving market of cancer therapeutics in Argentina.
South and Central America Cancer Therapeutics Market Country Insights
Based on region, the South and Central America cancer therapeutics market is further segmented into Mexico, Brazil, Argentina, Peru, Chile, Colombia. The Brazil held the largest share in 2024.
The market of cancer therapeutics in South and Central America is growing, driven by increasing incidence of cancer and development of treatment modalities. The major players are also driving the growth with their strategic moves. PharmaMar, a Spanish pharmaceutical firm, has received permission to submit a marketing authorization application to the European Medicines Agency for lurbinectedin (Zepzelca) + atezolizumab (Tecentriq) as a first-line maintenance therapy for small cell lung cancer that is advanced. Moreover, in May 2025, PharmaMar and its collaborative company, Adium Pharma S.A, through its subsidiary Raffo in Argentina, have obtained the marketing authorization for Zepzelca (lurbinectedin) from Argentina's National Administration of Drugs, Foods and Medical Devices (ANMAT) for adult patients with metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-based chemotherapy. Brazilian-based Eurofarma, a multinational organization, continues to be a market leader, distributing a wide range of pharmaceuticals, including oncology therapeutics, and growing its reach across South and Central America. Such drivers are indicative of an evolving and dynamic cancer therapeutics market in South and Central America.
South and Central America Cancer Therapeutics Market Company Profiles
Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Pfizer Inc; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; and AbbVie are among the key players operating in the market. These companies are engaged in collaborative drug development to bring novel therapeutics for cancer in the market, aiming to stay ahead on competitive edge.
South and Central America Cancer Therapeutics Market Research Methodology:
The following methodology has been followed for the collection and analysis of data presented in this report:
Secondary Research
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Company websites, annual reports, financial statements, broker analyses, and investor presentations Industry trade journals and other relevant publications Government documents, statistical databases, and market reports News articles, press releases, and webcasts specific to companies operating in the marketNote:All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.
Primary Research
Business Market Insights conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:
Refine findings from secondary research Enhance the expertise and market understanding of the analysis team Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:
Industry stakeholders:
Vice Presidents, business development managers, market intelligence managers, and national sales managers External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise Key Sources Referred:
US Magnetic Materials Association Cancer Therapeutics Division (PMD) The Magnetics Society (TMS) The American Magnetics Society (AMS) Rare Earth Industry Association (REIA)
Executive Summary and South and Central America Cancer Therapeutics Market Analysis:
The cancer therapeutics market in South and Central America is witnessing steady growth with increasing prevalence of cancer, the expansion of healthcare infrastructure, and augmented government programs for cancer treatment. Progress in targeted therapies, immunotherapies, and personalized medicine are improving the outcomes of the treatments in the region. Market growth is driven by Brazil and Argentina due to higher healthcare spending and accessibility of advanced treatments. Companies are focusing on strategic initiatives such as partnerships, clinical trials, and product launches to increase their regional footprint. With the market continuing to attract investment and create awareness, the market is likely to witness moderate but consistent growth over the next few years, with rich opportunities for innovation and market penetration.
South and Central America Cancer Therapeutics Market Segmentation Analysis:
Key segments that contributed to the derivation of the cancer therapeutics market analysis are therapy type, indication, and distribution channel.
By therapy type, the cancer therapeutics market is segmented into chemotherapy, targeted therapy, radiation therapy, hormone therapy, and other therapy types. The chemotherapy segment dominated the market in 2024. In terms of indications, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment held the largest share of the market in 2024. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment held the largest share of the market in 2024.
South and Central America Cancer Therapeutics Market Outlook
The South and Central America cancer therapeutics market is growing, with Brazil and Argentina becoming the contributors of market growth. In May 2022, In Brazil, pharmaceutical group Eurofarma has signed an agreement with Shanghai Henlius Biotech to manufacture biosimilars, thus making more cancer therapies available in South and Central America. The Brazilian government has also funded a CAR T-cell treatment trial for blood cancers undertaken by the University of São Paulo and the Butantan Institute. In Argentina, Hugo Sigman's Grupo Insud is a major biotechnology company, with its mAbxience subsidiary developing biosimilars for oncology. The Argentine government has been spearheading cancer research through initiatives like the National Cancer Institute with an aim to improve the delivery of treatment and promote public-private partnerships. The efforts indicate the dynamic and evolving market of cancer therapeutics in Argentina.
South and Central America Cancer Therapeutics Market Country Insights
Based on region, the South and Central America cancer therapeutics market is further segmented into Mexico, Brazil, Argentina, Peru, Chile, Colombia. The Brazil held the largest share in 2024.
The market of cancer therapeutics in South and Central America is growing, driven by increasing incidence of cancer and development of treatment modalities. The major players are also driving the growth with their strategic moves. PharmaMar, a Spanish pharmaceutical firm, has received permission to submit a marketing authorization application to the European Medicines Agency for lurbinectedin (Zepzelca) + atezolizumab (Tecentriq) as a first-line maintenance therapy for small cell lung cancer that is advanced. Moreover, in May 2025, PharmaMar and its collaborative company, Adium Pharma S.A, through its subsidiary Raffo in Argentina, have obtained the marketing authorization for Zepzelca (lurbinectedin) from Argentina's National Administration of Drugs, Foods and Medical Devices (ANMAT) for adult patients with metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-based chemotherapy. Brazilian-based Eurofarma, a multinational organization, continues to be a market leader, distributing a wide range of pharmaceuticals, including oncology therapeutics, and growing its reach across South and Central America. Such drivers are indicative of an evolving and dynamic cancer therapeutics market in South and Central America.
South and Central America Cancer Therapeutics Market Company Profiles
Astellas Pharma Inc; Eli Lilly and Co; Novartis AG; Merck KGaA.; Johnson & Johnson; AstraZeneca; Pfizer Inc; Bristol Myers Squibb; F. Hoffmann-La Roche Ltd; and AbbVie are among the key players operating in the market. These companies are engaged in collaborative drug development to bring novel therapeutics for cancer in the market, aiming to stay ahead on competitive edge.
South and Central America Cancer Therapeutics Market Research Methodology:
The following methodology has been followed for the collection and analysis of data presented in this report:
Secondary Research
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Company websites, annual reports, financial statements, broker analyses, and investor presentations Industry trade journals and other relevant publications Government documents, statistical databases, and market reports News articles, press releases, and webcasts specific to companies operating in the marketNote:All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.
Primary Research
Business Market Insights conducts a significant number of primary interviews each year with industry stakeholders and experts to validate and analyze the data and gain valuable insights. These research interviews are designed to:
Refine findings from secondary research Enhance the expertise and market understanding of the analysis team Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects Primary research is conducted via email interactions and telephone interviews with industry experts across various markets, categories, segments, and sub-segments in different regions. Participants typically include:
Industry stakeholders:
Vice Presidents, business development managers, market intelligence managers, and national sales managers External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise Key Sources Referred:
US Magnetic Materials Association Cancer Therapeutics Division (PMD) The Magnetics Society (TMS) The American Magnetics Society (AMS) Rare Earth Industry Association (REIA)
Table of Contents
150 Pages
- 1. Introduction
- 1.1 Business Market Insights Research Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Market Insights
- 2.2 Market Attractiveness
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
- 4. South and Central America Cancer Therapeutics Market Landscape
- 4.1 Market Overview
- 4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
- 4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
- 5. South and Central America Cancer Therapeutics Market – Key Market Dynamics
- 5.1 Growth Drivers
- 5.1.1 Rising Prevalence of Cancer
- 5.1.2 Favorable Reimbursement Scenario for Novel Therapeutics
- 5.1.3 Improvement in Diagnosis Rate of Cancer
- 5.2 Market Opportunities
- 5.2.1 Government Intervention across Developing Nations to Improve the Access of Life-saving Drugs
- 5.2.2 Rising Investments in the Development of Advanced Drug Development Platforms
- 5.2.3 Growing Number of Clinical trials for Anticancer Drugs
- 5.3 Future Trends
- 5.3.1 Emergence of Advanced Cell & Gene Therapies
- 5.3.2 Rising Adoption of Precision Medicine and Personalized Therapeutics
- 5.3.3 Improvement in Diagnosis Rate of Cancer
- 5.4 Impact of Drivers and Restraints
- 6. South and Central America Cancer Therapeutics Market Regional Analysis
- 6.1 South and Central America Cancer Therapeutics Market Overview
- 6.2 South and Central America Cancer Therapeutics Market Revenue 2021-2031 (US$ Million)
- 6.3 South and Central America Cancer Therapeutics Market Forecast Analysis
- 7. South and Central America Cancer Therapeutics Market Analysis – by Therapy Type
- 7.1 Chemotherapy
- 7.1.1 Overview
- 7.1.2 Chemotherapy: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 7.2 Targeted Therapy
- 7.2.1 Overview
- 7.2.2 Targeted Therapy: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 7.3 Radiation Therapy
- 7.3.1 Overview
- 7.3.2 Radiation Therapy: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 7.4 Hormone Therapy
- 7.4.1 Overview
- 7.4.2 Hormone Therapy: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 7.5 Other Therapy Types
- 7.5.1 Overview
- 7.5.2 Other Therapy Types: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8. South and Central America Cancer Therapeutics Market Analysis – by Indications
- 8.1 Blood Cancer
- 8.1.1 Overview
- 8.1.2 Blood Cancer: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Lung Cancer: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.3 Breast Cancer
- 8.3.1 Overview
- 8.3.2 Breast Cancer: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.4 Colorectal Cancer
- 8.4.1 Overview
- 8.4.2 Colorectal Cancer: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.5 Prostate Cancer
- 8.5.1 Overview
- 8.5.2 Prostate Cancer: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.6 Stomach Cancer
- 8.6.1 Overview
- 8.6.2 Stomach Cancer: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.7 Cervical Cancer
- 8.7.1 Overview
- 8.7.2 Cervical Cancer: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.8 Liver & Intrahepatic Bile Duct Cancer
- 8.8.1 Overview
- 8.8.2 Liver & Intrahepatic Bile Duct Cancer: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.9 Thyroid Cancer
- 8.9.1 Overview
- 8.9.2 Thyroid Cancer: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 8.10 Other Indications
- 8.10.1 Overview
- 8.10.2 Other Indications: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 9. South and Central America Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Other Indications: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Other Indications: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 9.3 Online Channel
- 9.3.1 Overview
- 9.3.2 Other Indications: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10. South and Central America Cancer Therapeutics Market – South and Central America Analysis
- 10.1 South and Central America
- 10.1.1 South and Central America Cancer Therapeutics Market Breakdown, by Key Country, 2025 and 2031 (%)
- 10.1.1.1 South and Central America Cancer Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.1.1.1 Brazil: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.1.1 Brazil: South and Central America Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.1.1.1.2 Brazil: South and Central America Cancer Therapeutics Market Breakdown, by Indications
- 10.1.1.1.3 Brazil: South and Central America Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.2 Argentina: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.2.1 Argentina: South and Central America Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.1.1.2.2 Argentina: South and Central America Cancer Therapeutics Market Breakdown, by Indications
- 10.1.1.2.3 Argentina: South and Central America Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.3 Chile: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.3.1 Chile: South and Central America Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.1.1.3.2 Chile: South and Central America Cancer Therapeutics Market Breakdown, by Indications
- 10.1.1.3.3 Chile: South and Central America Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.4 Peru: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.4.1 Peru: South and Central America Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.1.1.4.2 Peru: South and Central America Cancer Therapeutics Market Breakdown, by Indications
- 10.1.1.4.3 Peru: South and Central America Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.5 Colombia: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.5.1 Colombia: South and Central America Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.1.1.5.2 Colombia: South and Central America Cancer Therapeutics Market Breakdown, by Indications
- 10.1.1.5.3 Colombia: South and Central America Cancer Therapeutics Market Breakdown, by Distribution Channel
- 10.1.1.6 and Rest of SAM: South and Central America Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
- 10.1.1.6.1 and Rest of SAM: South and Central America Cancer Therapeutics Market Breakdown, by Therapy Type
- 10.1.1.6.2 and Rest of SAM: South and Central America Cancer Therapeutics Market Breakdown, by Indications
- 10.1.1.6.3 and Rest of SAM: South and Central America Cancer Therapeutics Market Breakdown, by Distribution Channel
- 11. Competitive Landscape
- 11.1 Heat Map Analysis
- 11.2 Company Positioning and Concentration
- 12. South and Central America Cancer Therapeutics Market Industry Landscape
- 12.1 Overview
- 12.2 Mergers and Acquisitions
- 12.3 Agreements, Collaborations, and Joint Ventures
- 12.4 New Product Launches
- 12.5 Expansions and Other Strategic Developments
- 13. Company Profiles
- 13.1 Astellas Pharma Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Eli Lilly and Co
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Novartis AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 Merck KGaA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 AstraZeneca
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Pfizer Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 Hoffmann-La Roche Ltd
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Johnson & Johnson
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 13.9 AbbVie Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
- 13.10 Bristol-Myers Squibb Co
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
- 14. Appendix
- 14.1 About Business Market Insights
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
